At the Radiological Society of North America (RSNA) annual meeting, a multitude of artificial intelligence (AI) technologies are on display, including GE HealthCare’s latest innovation, the MyBreastAI suite. This platform comprises a series of AI applications designed to aid in breast cancer detection and streamline workflows.
During the ongoing radiology conference in Chicago, US, from November 26-30, GE HealthCare unveiled over 40 new advancements, with the MyBreastAI suite standing out as a focal point of their AI-driven initiatives. This suite incorporates three AI tools sourced from iCAD’s ProFound Breast Health Suite, aimed at enhancing the breast imaging process.
These applications are instrumental in prioritizing cases by evaluating lesion scores, identifying areas of interest on mammograms, and standardizing assessments of breast density to minimize discrepancies among radiologists.
Pooja Pathak, GE HealthCare’s vice president and general manager of mammography, emphasized the significance of AI in mammography for early breast cancer detection, stating, “We continue to explore how we can leverage the power of AI in mammography to support the early detection of breast cancer.”
Initially, the MyBreastAI suite will be accessible in the US, marking a significant advancement in medical imaging propelled by AI. A forecast by GlobalData in 2023 predicts that the global revenue generated by AI platforms in healthcare will soar to $18.8 billion by 2027.
Despite the promising prospects of AI in healthcare, industry experts advocate for a robust digital infrastructure within healthcare systems to ensure the long-term success of AI integration.
GE HealthCare has been actively securing radiology clearances, with the recent announcement at RSNA of the US Food and Drug Administration (FDA) clearance for Critical Care Suite 2.1. This AI-powered tool aids in the detection and diagnosis of pneumothorax, alerting users to potential cases by overlaying suspected regions on X-rays. The algorithms embedded in the platform expedite diagnosis and enhance accuracy, boasting a 96% precision in identifying small pneumothoraxes and a flawless 100% accuracy rate for larger ones.
Furthermore, GE HealthCare received FDA clearance for an updated version of Digital Expert Access, enabling radiologists to remotely conduct magnetic resonance imaging (MRI) scans from any location.
Despite the positive momentum surrounding GE HealthCare’s technological advancements, the company’s shares experienced a decline following UBS’s downgrade from Neutral to Sell. This shift was attributed to a narrower earnings margin and a cautious market outlook.
